Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions , authorizing marketing of ADCETRIS for two lymphoma indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment ...
